{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:39:33Z","timestamp":1762868373924,"version":"3.41.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To report surgical observations formulated during the first 120 cases of subretinal gene therapy in patients with inherited retinal degenerations (IRDs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A two-surgeon team compiled surgical observations and formulated surgical pearls based on the consecutive cases of subretinal viral vector injection in patients enrolled in clinical trials focusing on choroideremia, achromatopsia, and RP GTPase regulator associated retinitis pigmentosa, as well as patients with retinal pigment epithelium-specific-65-kDa (RPE65) associated Leber congenital amaurosis receiving Food and Drug Administration-approved voretigene neparvovec-rzyl therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>One hundred twenty subretinal surgeries were performed by a two-surgeon team. Key anatomical features pertinent to surgical management were noted and are described in this article. Surgical decision making for successful subretinal administration of viral vectors and management of potential surgical challenges were formulated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Lessons learned during subretinal gene therapy cases may be helpful to other surgeons entering clinical trials or performing postapproval gene therapy administration. Surgical pearls outlined in this article may also be helpful for other targeted subretinal therapies, such as cellular transplantation or retinal prosthesis implantation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000003085","type":"journal-article","created":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T08:00:34Z","timestamp":1609142434000},"page":"1608-1611","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Surgical Observations From the First 120 Cases of Subretinal Gene Therapy for Inherited Retinal Diseases"],"prefix":"10.1097","volume":"43","author":[{"given":"Ninel Z.","family":"Gregori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250605","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fnins.2017.00174","article-title":"Retinal gene therapy: surgical vector delivery in the translation to clinical trials","volume":"11","author":"Ochakovski","year":"2017","journal-title":"Front Neurosci"},{"key":"R2-20250605","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"R3-20250605","doi-asserted-by":"crossref","first-page":"a017293","DOI":"10.1101\/cshperspect.a017293","article-title":"Gene therapy for choroideremia using an adeno-associated viral (AAV) vector","volume":"5","author":"Barnard","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R4-20250605","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1056\/NEJMc1509501","article-title":"Visual acuity after retinal gene therapy for choroideremia","volume":"374","author":"Edwards","year":"2016","journal-title":"N Engl J Med"},{"key":"R5-20250605","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1016\/j.ophtha.2016.06.041","article-title":"Gene therapy and stem cell transplantation in retinal disease: the new frontier","volume":"123","author":"MacLaren","year":"2016","journal-title":"Ophthalmology"},{"key":"R6-20250605","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41591-020-0763-1","article-title":"Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR","volume":"26","author":"Cehajic-Kapetanovic","year":"2020","journal-title":"Nat Med"},{"key":"R7-20250605","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/IAE.0000000000002609","article-title":"Surgical technique for subretinal gene therapy in humans with inherited retinal degeneration","volume":"39","author":"Davis","year":"2019","journal-title":"Retina"},{"article-title":"Intraoperative use of microscope-integrated optical coherence tomography for subretinal gene therapy delivery","author":"Gregori","key":"R8-20250605","doi-asserted-by":"crossref","DOI":"10.1097\/IAE.0000000000001646"},{"key":"R9-20250605","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/eye.2017.158","article-title":"Technique of retinal gene therapy: delivery of viral vector into the subretinal space","volume":"31","author":"Xue","year":"2017","journal-title":"Eye (Lond)"},{"key":"R10-20250605","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/IAE.0000000000001646","article-title":"Intraoperative use of microscope-integrated optical coherence tomography for subretinal gene therapy delivery","volume":"39","author":"Gregori","year":"2019","journal-title":"Retina"},{"key":"R11-20250605","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ajo.2018.09.012","article-title":"Choroideremia gene therapy phase 2 clinical trial: 24-month results","volume":"197","author":"Lam","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"R12-20250605","doi-asserted-by":"crossref","first-page":"xxv","DOI":"10.1016\/j.ajo.2018.08.038","article-title":"The blunt end: surgical challenges of gene therapy for inherited retinal diseases","volume":"196","author":"Davis","year":"2018","journal-title":"Am J Ophthalmol"},{"journal-title":"JAMA Ophthalmol","article-title":"Efficacy and safety of retinal gene therapy using adeno-associated virus vector for patients with choroideremia: a randomized clinical trial","author":"Fischer","key":"R13-20250605"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T17:07:55Z","timestamp":1749143275000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":13,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003085","relation":{},"ISSN":["0275-004X"],"issn-type":[{"type":"print","value":"0275-004X"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}